For many studies, biofluid samples are more easily available than tissue samples. Our Biofluid Biomarker Discovery service enables deep and reproducible quantification of biofluid proteomes. It allows the identification of the most promising, actionable biomarkers to support clinical decision making.
Biofluids are known to have a high protein dynamic range, requiring a highly robust technology for proteomic analysis. Our TrueDiscovery® platform for biofluid biomarker discovery enables the quantification of biofluid proteomes with unparalleled specificity and depth to identify differentially regulated proteins as biomarker candidates in an unbiased, hypothesis-free manner.
The application offers a proteome coverage of 4,200 proteins in plasma or serum, 6,100 proteins in cerebrospinal fluid (CSF), and 11,100 proteins in urine.
We offer a choice of depth of analysis and can identify low-abundant proteins thanks to our highly optimized depletion and sample enrichment workflow.
The service is scalable to thousands of samples with industry-leading throughput.
The platform is powered by Biognosys’ proprietary Hyper Reaction Monitoring (HRM™) technology and Spectronaut® software for Artificial Intelligence and Machine Learning (AI/ML) enhanced proteomics data analysis.
Insights from TrueDiscovery® studies can guide the choice of proteins in follow-on studies with TrueSignature® custom panels. Moreover, our biofluid-based profiling workflows can be combined with our proprietary PQ500™ plasma panel. PQ500 is a reference panel for absolute quantification, developed based on our expertise in targeted proteomics.
Harnessing the information present in the plasma proteome requires robust large-scale analytical techniques. Our latest white paper gives you a better understanding of two leading [...]
Our new White Paper explains how advances in mass spectrometry can now unlock the potential of the plasma proteome, uncovering actionable insights that are essential for biomarker [...]
Our new White Paper explains why oncology drug development fails and how Biognosys’ proteomics platforms and applications can support your oncology research.
The brochure provides an overview of the key features and benefits of our next-generation TrueDiscovery™ platform. In addition, it elaborates on our deep and reproducible proteom [...]
We describe a first-of-its-kind study using multi-omics biomarker approaches to demonstrate pharmacodynamic effects and immune modulation in pancreatic cancer. Biognosys’ proprie [...]
Watch our latest webinars "3D proteome snapshots enable high-resolution functional proteomics screens" and "Immunotherapy meets proteomics: A winning combination for clinical trial [...]
Plasma proteomics is increasingly recognized as a fundamental approach to accelerate biomarker discovery and drug development, taking precision medicine to the next level.
The case study elaborates on the results of our pan-cancer proteomics study. We analyzed 180 plasma samples from lung, breast, colorectal, pancreatic, and prostate cancer using our [...]
With the 3D Protein Explorer you can visualize the proteomic signature identified with our next-generation Plasma Biomarker Discovery solution in our latest pan-cancer clinical stu [...]
Immunotherapy significantly improved treatment options for patients with NSCLC. However, not all patients respond equally if at all. In a joint study with Curie Institute (Paris, F [...]
Cerebrospinal fluid (CSF) is established as a key matrix that enables interrogation of biological processes within the central nervous system. CSF biomarkers may support the develo [...]
This technical note provides an overview of the importance of plasma and serum as biospecimens in clinical practice, the challenges that large sample cohorts pose in MS-based prote [...]
Bruderer R et al. Molecular & Cellular Proteomics. We have established a robust capillary-flow DIA platform capable of measuring a large number of cli [...]
The results are presented and discussed with you in a dedicated conference call and delivered electronically in PDF and Excel formats.
a) Normalized relative protein intensities for all detected proteins or absolute quantities if stable isotope standards were used
b) Protein annotation (based on Uniprot Knowledgebase)
a) Differentially regulated proteins with regulation factor and p-value
b) Coefficient of variation analysis
c) Multivariate analysis (e.g. PCA)
d) Hierarchical clustering analysis
e) Functional analysis (e.g. GO/Pathway analysis)
f) Custom analysis upon request
Biofluid Biomarker Discovery can be applied on blood plasma or serum, urine, cerebrospinal fluid (CSF), or any other similar biofluid from any species
Biognosys is committed to providing the best possible results to our customers at the fastest possible project turnaround time.